INO Surges 266% on FDA Approval — How to Trade the Fade
Inovio Pharmaceuticals explodes 266% after FDA approves its RRP treatment. Volume hits 44.6M shares premarket. Here's what the setup means for traders now.
Key Points
- Inovio Pharmaceuticals has surged 266% after the FDA approved its treatment for Recurrent Respiratory Papillomatosis, with 44.6M shares traded in premarket alone against what is a structurally thin float.
- The move is a pure resolved binary catalyst — the approval overhang is gone, which historically marks the beginning of the fade cycle, not the continuation of the squeeze.
- Traders watching INO need a defined level and a time stop: the open-to-first-15-minute range will set the battlefield for whether momentum chasers or profit-takers control the session.
Inovio Pharmaceuticals is up 266% this morning. That single number requires no context to grab attention, but it requires significant context to trade — and the context here is almost entirely about what happens *after* a resolved binary catalyst in a thin-float biotech. The FDA approval of Inovio's treatment for Recurrent Respiratory Papillomatosis is the news. The 44.6 million shares already traded in premarket, against a stock printing $2.12, is the setup. These two facts together define both the opportunity and the danger in INO today.
What the FDA Just Did and Why It Moved the Stock This Much
Recurrent Respiratory Papillomatosis — RRP — is a rare disease caused by human papillomavirus infection that produces benign tumors in the airway. It is chronic, debilitating, and historically treated only through repeated surgical removal. An FDA-approved therapeutic changes the standard of care entirely, which is why this approval is not a marginal label expansion — it is category-defining for Inovio in a space the company has spent years pursuing. The binary nature of FDA decisions is exactly why stocks like INO trade flat for months before an approval decision, then gap violently the moment the outcome is known. The uncertainty premium disappears instantaneously.
Here is the structural problem that every momentum trader needs to understand before touching this name today: at $2.12 premarket, Inovio is a micro-cap with a thin float. The 44.6 million shares traded premarket — already an enormous number relative to any reasonable estimate of the stock's daily average volume — represents a massive concentration of speculative money entering at levels multiple times Monday's closing price. The spread between the overnight low of the gap and the premarket high is the entire range that early buyers are sitting on. Momentum chasers arriving at the open are, by definition, buying from people who got in cheaper and are now looking for an exit. That is not a bullish setup. That is the definition of a fade trade.
The Premarket Leaderboard Context — and What EVgo's 44% Move Tells You
INO does not exist in isolation this morning. The broader premarket gainers board is stacked with high-velocity, news-driven moves that collectively reflect a session where speculative capital is hyperactive even as the major indices bleed. ClearOne — ticker CLRO — is up 73% to $5.90 on 11.2 million shares. EVgo is up 44% to $1.81 on 23.4 million shares. Perion Network has added 31% to $11.38 on 2.2 million shares. Each of these names has its own catalyst, but their simultaneous appearance on the same morning leaderboard is a signal about market character: speculative money is concentrated in small-cap, news-driven names while institutional money rotates defensively in the large-cap space.
EVgo's 44% premarket surge deserves specific attention because it is the second-largest percentage mover on the board with nearly as much volume as INO in dollar-adjusted terms. EVgo at $1.81 is also a sub-$2 stock, which means it shares INO's structural characteristics: thin float, high short interest potential, and a price point where retail participation dominates institutional positioning. When two sub-$2 names both gap 40%-plus on the same morning, the market is in a momentum-tape environment for small caps — which means these moves can extend further than logic dictates, but reversals, when they come, are equally violent. The Yahoo Finance live markets desk has flagged the full premarket movers board as unusually active this session.
How Experienced Traders Are Playing This Setup
The textbook framework for a resolved binary catalyst in a thin-float name has three phases. Phase one is the gap itself — already complete. INO opened the premarket session at a price roughly 3.5 times its prior close, which means anyone who held through the binary event has already captured the maximum theoretical gain from the approval itself. Phase two is the open-range formation: the first 15 minutes of regular session trading establish the high and low that will define whether this is a "gap and go" or a "gap and fade." In a gap-and-go scenario, the stock consolidates near the open and breaks to new highs on sustained volume — typically requiring a new buyer demographic to enter above the open. In a gap-and-fade scenario, early sellers overwhelm new buyers, and the stock retraces a significant portion of the overnight gap. For stocks gapping 200%-plus on thin floats, the historical base rate strongly favors the fade.
Phase three — and this is where longer-term positioning becomes possible — is the post-volatility base. If INO fades from its open, there will be a price level where the fundamental buyers, the analysts who now need to re-rate the stock based on the RRP market opportunity, and the biotech-specific funds that accumulate after FDA resolutions begin to establish real positions. That level is not knowable premarket. It emerges from the session's price action. The key metric to watch intraday is volume profile: if selling volume exceeds buying volume on every attempt to push above the VWAP in the first hour, the fade thesis is intact.
There is a separate consideration for the stock's longer-term valuation reset. RRP is a rare disease, which means Inovio's addressable market, while real, is not a blockbuster commercial opportunity measured in billions of annual doses. The approval changes the company's regulatory status and de-risks its pipeline credibility, but revenue modeling for an RRP therapeutic is a specialty exercise. Analysts who had zero probability assigned to this approval will now initiate or reactivate coverage, and price target revisions will flow through Bloomberg's coverage and the wire services through the day — which creates headline risk in both directions.
The trade today is not "buy the FDA approval." That trade was yesterday, for whoever held the binary. The trade today is either a disciplined short against the open-range high with a tight stop above the first 15-minute candle, or a patient wait for the post-fade base to form in the afternoon session — ideally after volume has dried up and the stock has found a price where sellers are exhausted. That level, wherever it lands, is the entry for anyone who wants exposure to the legitimate fundamental re-rating that a first-ever FDA-approved RRP therapeutic justifies. Until then, the 44.6 million shares of premarket volume are a warning, not an invitation.
The Weekly Investor
Daily market analysis for active traders. Free.
